These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9574706)

  • 21. Mortality risks associated with empirical antibiotic activity in Escherichia coli bacteraemia: an analysis of electronic health records.
    Yoon CH; Bartlett S; Stoesser N; Pouwels KB; Jones N; Crook DW; Peto TEA; Walker AS; Eyre DW
    J Antimicrob Chemother; 2022 Aug; 77(9):2536-2545. PubMed ID: 35723965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Area of technical uncertainty for susceptibility testing of amoxicillin/clavulanate against Escherichia coli: analysis of automated system, Etest and disk diffusion methods compared to the broth microdilution reference.
    Soares A; Pestel-Caron M; Leysour de Rohello F; Bourgoin G; Boyer S; Caron F
    Clin Microbiol Infect; 2020 Dec; 26(12):1685.e1-1685.e6. PubMed ID: 32151599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Escherichia coli eradication from the blader urine by amoxicillin-sulbactam. Intrinsic activity of the inhibitor].
    Casellas JM; Visser M; Tomé G; Cohen H; Soutric J; Arenoso H
    Enferm Infecc Microbiol Clin; 2001 May; 19(5):206-10. PubMed ID: 11446908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reconciling the Potentially Irreconcilable? Genotypic and Phenotypic Amoxicillin-Clavulanate Resistance in
    Davies TJ; Stoesser N; Sheppard AE; Abuoun M; Fowler P; Swann J; Quan TP; Griffiths D; Vaughan A; Morgan M; Phan HTT; Jeffery KJ; Andersson M; Ellington MJ; Ekelund O; Woodford N; Mathers AJ; Bonomo RA; Crook DW; Peto TEA; Anjum MF; Walker AS
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32205351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia.
    Torumkuney D; Mayanskiy N; Edelstein M; Sidorenko S; Kozhevin R; Morrissey I
    J Antimicrob Chemother; 2018 Apr; 73(suppl_5):v14-v21. PubMed ID: 29659881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing
    Al-Tamimi M; Abu-Raideh J; Albalawi H; Shalabi M; Saleh S
    Microb Drug Resist; 2019 Oct; 25(8):1132-1141. PubMed ID: 31107146
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G; Berry V
    Antimicrob Agents Chemother; 1999 Jan; 43(1):35-40. PubMed ID: 9869562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro susceptibilities of Escherichia coli and Klebsiella spp. to ampicillin-sulbactam and amoxicillin-clavulanic acid.
    Kacmaz B; Sultan N
    Jpn J Infect Dis; 2007 Jul; 60(4):227-9. PubMed ID: 17642541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S; Marre R
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consequences of switching from a fixed 2 : 1 ratio of amoxicillin/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli.
    Leverstein-van Hall MA; Waar K; Muilwijk J; Cohen Stuart J;
    J Antimicrob Chemother; 2013 Nov; 68(11):2636-40. PubMed ID: 23766488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro susceptibility of Staphylococcus aureus towards amoxycillin-clavulanic acid, penicillin-clavulanic acid, dicloxacillin and cefuroxime.
    Skov R; Frimodt-Møller N; Espersen F
    APMIS; 2002 Aug; 110(7-8):559-64. PubMed ID: 12390414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.
    MacGowan AP; Noel AR; Rogers CA; Bowker KE
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2599-603. PubMed ID: 15215115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiological survey of amoxicillin-clavulanate resistance and corresponding molecular mechanisms in Escherichia coli isolates in France: new genetic features of bla(TEM) genes.
    Leflon-Guibout V; Speldooren V; Heym B; Nicolas-Chanoine M
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2709-14. PubMed ID: 10991849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
    Skarp KP; Shams A; Montelin H; Lagerbäck P; Tängdén T
    Int J Antimicrob Agents; 2019 Jan; 53(1):74-79. PubMed ID: 30236958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro activities of amoxicillin-clavulanic acid, cefuroxime, cephalexin, and cephalothin against trimethoprim-resistant Escherichia coli isolated from stools of children attending day-care centers.
    Singh KV; Reves RR; Pickering LK; Murray BE
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2047-9. PubMed ID: 2073095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro susceptibilities of 180 clinical isolates of Haemophilus influenzae to ampicillin, amoxycillin/clavulanate, cefaclor, cefuroxime, cefotaxime, clarithromycin, and azithromycin.
    Delmée M; Carpentier M; Glupczynski Y; Gordts B; Magerman K; Simon A; Surmont I; Van de Vyvere M; Van Landuyt H; Van Nimmen L; Van Noyen R
    Acta Clin Belg; 1996; 51(4):237-43. PubMed ID: 8858889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ex vivo pharmacodynamics of amoxicillin-clavulanate against beta-lactamase-producing Escherichia coli in a yucatan miniature pig model that mimics human pharmacokinetics.
    Bronner S; Murbach V; Peter JD; Levêque D; Elkhaïli H; Salmon Y; Dhoyen N; Monteil H; Woodnutt G; Jehl F
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3782-9. PubMed ID: 12435677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
    Pottumarthy S; Fritsche TR; Sader HS; Stilwell MG; Jones RN
    Int J Antimicrob Agents; 2005 Apr; 25(4):282-9. PubMed ID: 15784306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.